2026 · 3rd Quarter (July 1 - Sep 30)

RARE DISEASE COMPANY COALITION

Filed by RARE DISEASE COMPANY COALITION.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 15, 2026
Income: Not reported
Expenses: $80,000.00
Registrant: RARE DISEASE COMPANY COALITION
Client: RARE DISEASE COMPANY COALITION
Filing UUID: c5955a4e-db81-40c3-9026-e0f813d40dda
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit

Literal federal measure citations: H.R. 10359, H.R. 1532, S. 822, H.R. 1414

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.